About New Report on Hormone Refractory (Castration Resistant, Androgen-independent) Prostate Cancer – Pipeline Review H2, 2012″

December 17, 2012 by  
Filed under Prostate Cancer News

There have been so many reports and researches about prostate cancer. One you may really want to get know about is Global Markets Direct’s new report “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2012”.

Its an important review that could provide you latest updates and features of what’s going in the research of late prostate cancer. The article below is an extract that reveals vital details about this now important report about prostate cancer:

Research and Markets (http://www.researchandmarkets.com/research/m3plgs/hormone) has announced the addition of Global Markets Direct’s new report “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2012” to their offering.

Global Markets Direct’s, ‘Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2012’, provides an overview of the indication’s therapeutic

This report provides information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.

Scope

– A snapshot of the global therapeutic scenario for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.

– A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Source.

The above extract reveals quite some informative details about the report on new “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer – Pipeline Review, H2 2012”.

You can get more information about report from the Global Markets Direct website. Here you get to know more about castration-resistant prostate cancer.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Androgen -Independent Prostate Cancer – Information That SHOULD be Useful to You
  2. Side Effects Of Prostate Cancer Androgen Hormone Therapy and Androgen Independent Prostate Cancer
  3. Management of Castration-Resistant Prostate Cancer
  4. Scientists Discover a Molecular Switch Which Could Cause the Spread of Castration – Resistant Prostate Cancer
  5. How Hormone Refractory Prostate Cancer (HRPC) is Treated
  6. Review on New Drugs that Targets Androgen Production in Prostate Cancer
  7. MicroRNA 125b, a Molecule and new Target for Castration Resistant Prostate Cancer Identified
  8. Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial
  9. Chemotherapy Prostrate Cancer for Hormone Refractory Metastatic
  10. Cabozantinib (XL184) effective in Treating Castration-Resistant Prostate Cancer (CRPC) – Study
  11. Cancer Hormone Prostate Refractory and Chemotherapy for Hormonal Refractory Prostate Cancer
  12. Side Effects Of Prostate Cancer Androgen Hormone Therapy
  13. US Oncologists to Prescribe Enzalutamide for Metastatic Castration-resistant Prostate cancer (mCRPC)
  14. Prostate Cancer Androgen Hormone Therapy Side Effects
  15. Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)

Speak Your Mind

Tell us what you're thinking... !

s